Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Melanoma 3Carcinoma, Renal Cell 2Uveal Melanoma 1Urologic Neoplasms 1Skin Neoplasms 1Neoplasms 1Leukemia, Promyelocytic, Acute 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia 1Kidney Neoplasms 1

Interventions

Cytarabine 6Idarubicin 4Vorinostat 3Tretinoin 3Etoposide 3Daunorubicin 3Azacitidine 3romidepsin 2Thioguanine 2Sorafenib 2Radiotherapy 2Mitoxantrone 2Methotrexate 2Mercaptopurine 2Lenalidomide 2Cyclophosphamide 2sargramostim 1perifosine 1octadecyl-(N,N-dimethylpiperidino-4-yl)-phosphate 1merphos 1ispinesib 1flt3 ligand protein 1entinostat 1belinostat 1Peripheral Blood Stem Cell Transplantation 1Homoharringtonine 1Filgrastim 1Drug Therapy 1Decitabine 1CK0238273 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Leukemia, Promyelocytic, Acute × flt3 ligand protein × Clear all
NCT00006223 2013-06-24

flt3L in Treating Patients With Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 3 Completed
Other hematologic neoplasm

Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡